Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Victor Ryzhenko has a total of 65 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cardioprotective Effects of Coupled SH/NO System Modulators in a Rat Model of Doxorubicin-Induced Heart Failure

    by Victor Ryzhenko, Igor Belenichev, Olena Popazova, Nina Bukhtiyarova, Sergiy Oliynyk, Pavlo Petakh, Iryna Halabitska, Oleksandr Kamyshnyi

    Background: The high prevalence of chronic heart failure (CHF) in industrialized countries, alongside its grave consequences—including increased mortality, disability, functional impairment, and reduced quality of life—underscores the urgent need to optimize core medical therapy. In this regard, metabolic cardioprotectants are of particular interest, as their action is aimed at interrupting or mitigating the cascade of adverse metabolic reactions and enhancing the compensatory and adaptive mechanisms of the heart. The aim of this study was to evaluate the effect of sulfur-containing pharmacological agents—namely, N-acetylcysteine (NAC), Heptral, Thiotriazoline, and Angiolin—on selected parameters of the NO and thiol-disulfide systems in the hearts of rats with experimental doxorubicin-induced CHF, followed by an assessment of their cardioprotective efficacy. Methods: CHF was modeled in 70 male Wistar rats weighing 180–190 g by intraperitoneal administration of doxorubicin at a cumulative dose of 15 mg/kg, divided into 6 injections over 14 days. The investigated drugs were administered intragastrically once daily as a suspension in 1% starch mucilage for 30 days following the 14-day doxorubicin protocol: Angiolin ([(S)-2,6-diaminohexanoic acid 3-methyl-1,2,4-triazolyl-5-thioacetate], 100 mg/kg), Thiotriazoline (morpholinium thiazotate, 100 mg/kg), NAC (100 mg/kg), Heptral (S-adenosylmethionine, 100 mg/kg), and Mildronate (250 mg/kg). In the rat myocardium, key components of the NO and thiol-disulfide systems—iNOS, eNOS, nitrotyrosine, stable NO metabolites, glutathione peroxidase-4 (GPX4), glutathione reductase (GR), reduced glutathione (GSH), and oxidized glutathione (GSSG)—were determined using enzyme-linked immunosorbent assay (ELISA), biochemical assays, and real-time PCR. In serum, cardio-specific biomarkers were measured, including the creatine kinase-MB isoenzyme (CK-MB), N-terminal pro-B-type natriuretic peptide (NT-proBNP), and soluble ST2 protein (sST2). Results: It was established that on day 45 following the 14-day doxorubicin administration, alongside a significant elevation in CK-MB, NT-proBNP, and sST2 levels (p < 0.05), there was a concurrent upregulation of iNOS mRNA expression, iNOS protein levels, and nitrotyrosine formation, accompanied by a downregulation of eNOS mRNA expression, eNOS protein levels, and stable NO metabolites (p < 0.05). Furthermore, heart tissue from CHF rats exhibited depletion of the glutathione pool within the thiol-disulfide system, characterized by decreased GPX4, GR, and GSH levels alongside increased GSSG concentrations (p < 0.05). Course administration of the test pharmacological agents to experimental animals post-CHF induction resulted in an improvement in the evaluated parameters of the coupled NO and thiol-disulfide systems, as well as overall cardioprotection. The study analysis demonstrated that Angiolin was statistically superior to Heptral and Mildronate, whereas Thiotriazoline and NAC outperformed Mildronate. Conclusions: These findings confirm the potential cardioprotection provided by modulators of the SH/NO system. Based on these results, further preclinical investigation of Angiolin as a promising cardioprotective agent for CHF is experimentally substantiated.

  • Open Access

    A multi-agent GraphRAG framework for pharmacotherapy safety verification in clinical decision support systems

    by Victor Ryzhenko, Bogdan Burlaka, Igor Belenichev, Kristina Burlaka, Olena Aliyeva, Nina Bukhtiyarova, Iryna Halabitska, Pavlo Petakh, Oleksandr Kamyshnyi

    Background: The management of pharmacotherapy in patients with multimorbidity and polypharmacy is a difficult task in routine clinical practice. Clinicians must consider diagnoses, prescribed drugs, contraindications, drug-drug interactions, renal and hepatic function, laboratory values, dose limits and individual risk factors. Clinical decision support systems in traditional settings are based on static rules, and hard to update. Standalone large language models are capable of processing clinical language but their outputs may be unsupported by evidence, incomplete or out of date. In this study, we developed and evaluated a hybrid multi-agent GraphRAG framework for personalised pharmacotherapy safety verification. Methods: We developed a system that integrates graph based retrieval with large language models. The framework was composed of three parts: (1) a schema for a pharmacotherapy knowledge graph that encoded indications, contraindications, interactions, laboratory thresholds, dose limitations and relevant patient conditions; (2) an Extractor–Critic workflow that transformed unstructured medical text into graph elements with quality checks prior to their incorporation; and (3) a retrieval and re-ranking module that leveraged semantic search, graph traversal and safety-directed scoring. The system was evaluated on 12 benchmark cases extraction and 30 clinical safety questions answering. Comparison of conventional RAG and GraphRAG was done using linear mixed effects models, permutation testing, and paired case-level analysis. Results: The multi-agent extraction workflow beat the zero-shot baseline. Strict F1 improved by 0.156 points ( p < 0.01), mainly due to higher ecall (+0.172, p < 0.001). For clinical question answering, we found that GraphRAG outperformed conventional RAG in terms of medical accuracy (0.545 vs. 0.443, absolute difference of 0.102, p = 0.04). GraphRAG provided the better answer 66.7% of the time. The advantage was greatest where safety was dependent on contra-indications, laboratory cut-offs or patient specific factors. Smaller models performed as well as the larger models with the same GraphRAG configuration. Conclusion: The evaluation revealed that the integration of LLM-based extraction with a pharmacotherapy knowledge graph enhanced safety-oriented clinical decision support. GraphRAG provided more accurate and traceable answers than traditional RAG. Routine adoption will require validation on larger graphs, a wider range of datasets and real clinical populations, but this approach may be appropriate for cost sensitive and privacy conscious workflows.


  • Open Access

    Preclinical Study of the Neuroprotective Effects of Pharmacological Agent-Modulators of HSP70 After Intrauterine Hypoxia

    by Igor Belenichev, Olena Aliyeva, Nina Bukhtiyarova, Victor Ryzhenko, Sergiy Oliynyk, Suyeon Lee, Kyu-Ho Yi

    Background:Chronic intrauterine hypoxia (IUH) is a cause not only of early postnatal mortality but also of delayed central nervous system (CNS) impairments in offspring, including increased risks of acute cerebrovascular disorders, epilepsy, and neurodegenerative diseases. The above necessitates the urgent development of targeted neuroprotective strategies for newborns following IUH. The aim of the present study was to evaluate the neuroprotective effects of the 70 kDa heat shock protein (HSP70) modulators (angiolin, thiotriazolin, cerebrocurin, tamoxifen, glutaredoxin, and heat shock factor 1 (HSF-1)), as well as reference drugs, based on their impact on molecular markers of endothelial dysfunction (vascular endothelial growth factor A (VEGF-A), endothelial nitric oxide synthase (eNOS), inducible nitric oxide synthase (iNOS), nitrotyrosine), brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and caspase-8 in the brains of offspring after IUH at 1 and 2 months of age.Methods:Chronic hemic IUH was modeled in pregnant rats by daily administration of sodium nitrite (50 mg/kg, intraperitoneally) on days 16–21 of pregnancy. The male offspring were treated with the study drugs for 30 days starting on P1. Brain homogenates of offspring at P30 and P60 were analyzed using enzyme-linked immunosorbent assay (ELISA) for VEGF-A, eNOS, iNOS, nitrotyrosine, BDNF, NGF, and caspase-8.Results:IUH caused persistent endothelial dysfunction, characterized by decreased VEGF and eNOS levels, and nitrosative stress, associated with increased iNOS and nitrotyrosine levels. These changes were accompanied by decreased neurotrophin levels, including BDNF and NGF, and increased caspase-8 levels. Course administration of angiolin, cerebrocurin, HSF-1, thiotriazolin, and glutaredoxin improved the eNOS/iNOS balance, increased VEGF levels, and decreased nitrotyrosine levels, with the effect persisting until P60. Cerebrocurin and angiolin demonstrated the strongest recovery of neurotrophic factors (normalization or exceeding normal BDNF/NGF levels by P60) and effectively suppressed caspase-8 to near-normal levels. A positive correlation was established between BDNF, NGF, and HSP70 levels.Conclusions:Pharmacological modulators of HSP70 provide effective multimodal neuroprotection due to endothelioprotective and neurotrophic effects. Angiolin and Cerebrocurin demonstrate significant therapeutic potential, offering a promising strategy for mitigating the long-term neurological sequelae of IUH.

  • Open Access

    The Influence of Basic Therapy and New Drugs on NO-Dependent Mechanisms of Cardiac Destruction in Chronic Heart Failure

    by Igor Belenichev, Olena Popazova, Olexiy Goncharov, Nina Bukhtiyarova, Victor Ryzhenko, Denys Semenov, Sergiy Oliynyk, Pavlo Petakh, Oleksandr Kamyshnyi

    Chronic heart failure (CHF) remains a leading cause of global mortality, characterized by profound molecular and biochemical disturbances, including nitric oxide (NO) system dysfunction, mitochondrial impairment, and oxidative stress. While standard therapies such as ACE inhibitors, SGLT2 inhibitors, and beta-blockers address clinical symptoms, their capacity to interrupt the underlying biochemical mechanisms of cardiomyopathy is often limited. This review examines the pathophysiological role of impaired NO production and reactive oxygen species (ROS) accumulation in exacerbating myocardial contractile dysfunction and disease progression. Special focus is directed toward the development of next-generation β1-blockers with multifunctional properties, including antioxidant, NO-mimetic, and antiapoptotic effects. Evidence suggests that the novel compound Hypertril (1-(β-phenylethyl)-4-amino-1,2,4-triazolium bromide) exhibits significant cardioprotective potential. Experimental data indicate that Hypertril improves eNOS/iNOS expression and enhances NO bioavailability more effectively than conventional β-blockers, leading to stabilized ECG parameters and restored energy metabolism. These findings underscore the clinical relevance of developing NO-mimetic agents to optimize the pharmacological management of CHF.


  • Discovery and Characterization of Novel Spirotriazoloquinazolines as Potential Neuroprotectors: Synthesis, Computational Screening, and Preliminary In Vivo Evaluation

    by Kostiantyn Shabelnyk, Lyudmyla Antypenko, Natalia Bohdan, Victor Ryzhenko, Igor Belenichev, Pavlo Petakh, Oleksandr Kamyshnyi, Serhii Kovalenko

    This study describes the rational design, synthesis, and evaluation of forty 2′‐R‐6′ H ‐spiro(cycloalkyl/heterocyclyl)[1,2,4]triazolo[1,5‐ c ]quinazolines as potential neuroprotective agents targeting multiple receptor systems implicated in cognitive dysfunction. The molecular design integrated structural features from established nootropic and anxiolytic pharmacophores to create compounds with putative multi‐target activity. In silico ADMET analyses assessed drug‐likeness parameters, while molecular docking studies evaluated binding interactions with nine neuroreceptor targets: glutamate GluA3, GABA(A)R, dopamine D2, serotonin 5‐HT1A and 5‐HT7, cannabinoid CB2, muscarinic M2 acetylcholine, corticotropin‐releasing factor receptor 1 (CRF1R), and metabotropic glutamate receptor 5 (mGluR5). Based on computational predictions, selected compounds underwent preliminary in vivo screening using a ketamine‐induced cognitive impairment model in rats. Behavioral assessments examined anxiety‐related responses and cognitive performance relative to piracetam and fabomotizole controls. Biochemical analyses measured inflammatory markers (IL‐1β, caspase‐1), cell survival indicators (Bcl‐2), and hypoxic adaptation responses (HIF‐1 mRNA). Docking studies indicated favorable binding profiles across tested receptor targets compared to reference ligands, with calculated affinities suggesting potential modulatory interactions. The experiments showed that compounds 25 , 26 , and 32 attenuated ketamine‐induced behavioral alterations, demonstrating effects in anxiety reduction and cognitive performance that appeared numerically greater than piracetam and fabomotizole, though the magnitude and statistical robustness of these differences require further characterization. Compound 31 reduced IL‐1β expression by 72% and caspase‐1 by 80% relative to ketamine‐treated controls. Compound 26 increased Bcl‐2 expression by 96% and HIF‐1 mRNA levels by 3.5‐fold compared to control conditions. These findings suggest that spirotriazoloquinazolines may function as positive modulators at cognitive‐enhancing receptors, potentially exerting neuroprotective effects through anti‐inflammatory and anti‐apoptotic mechanisms. Further investigation is necessary to validate the observed effects, establish dose–response relationships, and elucidate the molecular mechanisms underlying the apparent neuroprotective properties of these compounds. image

  • Open Access

    Initial Discovery and Characterization of Novel Spirotriazoloquinazolines as Potential Neuroprotectors: Synthesis, Computational Screening, and Preliminary In Vivo Evaluation

    by Kostiantyn Shabelnyk, Lyudmyla Antypenko, Natalia Bohdan, Victor Ryzhenko, Igor Belenichev, Oleksandr Kamyshnyi, Serhii Kovalenko

    Ketamine anesthesia frequently causes postoperative cognitive dysfunction as the primary clinical concern, with potential broader applications to trauma-related cognitive disorders. This study explores novel neuroprotectives, targeting multiple pathways through design, synthesis, and evaluation of forty 2'-R-6'H-spiro(cycloalkyl/heterocyclyl)[1,2,4]triazolo[1,5-c]quinazolines. Molecular docking showed superior binding affinities to GluA3 compared to references, additionally to favorable drug-likeness ADMET. Selected compounds were tested in ketamine-induced cognitive impairment rat models with assessment in vivo. Compounds 25, 26, and 32 effectively normalized ketamine-disrupted behavioral parameters, reducing anxiety and improving cognitive function more effectively than piracetam and fabomotizole. 31 showed potent anti-inflammatory effects (72% reduction in IL-1β, 80% - in caspase-1), while 26 enhanced cell survival pathways (96% increase in Bcl-2) and hypoxic adaptation (3.5-fold increase in HIF-1 mRNA). These novel spirotriazoloquinazolines function as positive modulators of cognitive-enhancing receptors (GABA(A), GluA3), rather than direct antagonists, demonstrating neuroprotective properties through anti-inflammatory, anti-apoptotic, and adaptive pathway modulation, while definitive classification requires functional validation.

  • Open Access

    Molecular and Biochemical Mechanisms of Cardiomyopathy Development Following Prenatal Hypoxia—Focus on the NO System

    by Olena Popazova, Igor Belenichev, Nina Bukhtiyarova, Victor Ryzhenko, Nadia Gorchakova, Valentyn Oksenych, Oleksandr Kamyshnyi

    Prenatal hypoxia (PH) adversely affects the development of the fetal heart, contributing to persistent cardiovascular impairments in postnatal life. A key component in regulating cardiac physiology is the nitric oxide (NO) system, which influences vascular tone, myocardial contractility, and endothelial integrity during development. Exposure to PH disrupts NO-related signaling pathways, leading to endothelial dysfunction, mitochondrial damage, and an escalation of oxidative stress—all of which exacerbate cardiac injury and trigger cardiomyocyte apoptosis. The excessive generation of reactive nitrogen species drives nitrosative stress, thereby intensifying inflammatory processes and cellular injury. In addition, the interplay between NO and hypoxia-inducible factor (HIF) shapes adaptive responses to PH. NO also modulates the synthesis of heat shock protein 70 (HSP70), a critical factor in cellular defense against stress. This review emphasizes the involvement of NO in cardiovascular injury caused by PH and examines the cardioprotective potential of NO modulators—Angiolin, Thiotriazoline, Mildronate, and L-arginine—as prospective therapeutic agents. These agents reduce oxidative stress, enhance endothelial performance, and alleviate the detrimental effects of PH on the heart, offering potential new strategies to prevent cardiovascular disorders in offspring subjected to prenatal hypoxia.


  • Open Access

    Molecular and Biochemical Mechanisms of Cardiomyopathy Development Following Prenatal Hypoxia—Focus on the NO System

    by Olena Popazova, Igor Belenichev, Nina Bukhtiyarova, Victor Ryzhenko, Nadia Gorchakova, Valentyn Oksenych, Oleksandr Kamyshnyi

    Prenatal hypoxia (PH) disrupts fetal heart development and induces persistent cardiovascular dysfunction in offspring. The nitric oxide (NO) system is pivotal in regulating myocardial function, influencing vascular tone, contractility, and endothelial integrity during development. PH alters NO signaling, leading to endothelial dysfunction, mitochondrial damage, and oxidative stress, which exacerbate myocardial impairment and increase cardiomyocyte apoptosis. Elevated nitrosative stress, through excessive reactive nitrogen species, further exacerbates these effects, promoting inflammation and cellular injury. The interaction between NO and hypoxia-inducible factor (HIF) also mediates adaptive responses to PH. Additionally, NO modulates the expression of heat shock protein 70 (HSP70), providing cellular protection under stress. This review highlights the role of NO in PH-induced cardiovascular damage and evaluates the therapeutic potential of NO modulators—Angiolin, Tiotriazoline, Mildronate, and L-arginine—as promising agents for cardioprotection. These compounds mitigate oxidative stress, improve endothelial function, and counteract the adverse effects of PH on the heart, suggesting novel therapeutic strategies for preventing cardiovascular dysfunction in offspring exposed to prenatal hypoxia.


  • Open Access

    Targeting Mitochondrial Dysfunction in Cerebral Ischemia: Advances in Pharmacological Interventions

    by Igor Belenichev, Olena Popazova, Nina Bukhtiyarova, Victor Ryzhenko, Sergii Pavlov, Elina Suprun, Valentyn Oksenych, Oleksandr Kamyshnyi

    The study of mitochondrial dysfunction has become increasingly pivotal in elucidating the pathophysiology of various cerebral pathologies, particularly neurodegenerative disorders. Mitochondria are essential for cellular energy metabolism, regulation of reactive oxygen species (ROS), calcium homeostasis, and the execution of apoptotic processes. Disruptions in mitochondrial function, driven by factors such as oxidative stress, excitotoxicity, and altered ion balance, lead to neuronal death and contribute to cognitive impairments in several brain diseases. Mitochondrial dysfunction can arise from genetic mutations, ischemic events, hypoxia, and other environmental factors. This article highlights the critical role of mitochondrial dysfunction in the progression of neurodegenerative diseases and discusses the need for targeted therapeutic strategies to attenuate cellular damage, restore mitochondrial function, and enhance neuroprotection.


  • Open Access

    Possibility of Using NO Modulators for Pharmacocorrection of Endothelial Dysfunction After Prenatal Hypoxia

    by Igor Belenichev, Olena Popazova, Oleh Yadlovskyi, Nina Bukhtiyarova, Victor Ryzhenko, Sergii Pavlov, Valentyn Oksenych, Oleksandr Kamyshnyi

    Prenatal hypoxia (PH) is a key factor in the development of long-term cardiovascular disorders, which are caused by various mechanisms of endothelial dysfunction (ED), including those associated with NO deficiency. This emphasizes the potential of therapeutic agents with NO modulator properties, such as Thiotriazoline, Angiolin, Mildronate, and L-arginine, in the treatment of PH. Methods: Pregnant female rats were given a daily intraperitoneal dose of 50 mg/kg of sodium nitrite starting on the 16th day of pregnancy. A control group of pregnant rats received saline instead. The resulting offspring were divided into the following groups: Group 1—intact rats; Group 2—rat pups subjected to prenatal hypoxia (PH) and treated daily with physiological saline; and Groups 3 to 6—rat pups exposed to prenatal hypoxia and treated daily from the 1st to the 30th day after birth. Levels of sEPCR, Tie2 tyrosine kinase, VEGF-B, SOD1/Cu-Zn SOD, GPX4, and GPX1 in the heart’s cytosolic homogenate were assessed using ELISA. The expression of VEGF and VEGF-B mRNA was analyzed via real-time polymerase chain reaction, and the nuclear area of myocardial microvessel endothelial cells was evaluated morphometrically. Results: We have shown that only two representatives of this group—Angiolin and Thiotriazoline—are able to exert full effect on the indices of endothelial dysfunction after PH to decrease sEPCR, increase Tie-2, VEGF-B and VEGF-B mRNA, Cu/ZnSOD, and GPX in myocardial cytosol, and increase the area of endotheliocyte nuclei in 1- and 2-month-old rats in comparison with the control. Conclusions: Our results experimentally substantiate the necessity of early postnatal cardio- and endothelioprotection using NO modulators, taking into account the role of NO-dependent mechanisms in the pathogenesis of cardiovascular system disorders in neonates after PH.